<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413644</url>
  </required_header>
  <id_info>
    <org_study_id>B88558</org_study_id>
    <nct_id>NCT03413644</nct_id>
  </id_info>
  <brief_title>Evaluation of ClearLLab Leukemia and Lymphoma Panels</brief_title>
  <official_title>Evaluation of ClearLLab Leukemia and Lymphoma Panels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckman Coulter, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as
      part of their standard of care for hematological diseases work-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center study of specimens from subjects presenting for flow cytometry immunophenotyping
      as part of their standard of care for hematological diseases work-up. Residual specimens will
      be tested using the ClearLLab Panels to determine the presence or absence of an abnormal
      phenotype and compare results to clinical impression (hematological malignancy or
      non-malignancy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Anticipated">July 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hematologically Malignant or Non-Malignant</measure>
    <time_frame>Residual samples must be tested within 24 hours of collection in K2EDTA or within 48 hours of collection in Heparin or ACD anticoagulants</time_frame>
    <description>Presence or absence of an abnormal phenotype detected using the ClearLLab Panels vs. the clinical outcome of &quot;Hematologically Malignant&quot; or &quot;Hematologically Non-Malignant&quot; from the same subject</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Leukemia-Lymphoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow Cytometry</intervention_name>
    <description>Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Specimens from new cases or follow up patients suspected of having a hematological
        malignancy and present with symptoms based on Bethesda guidelines.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Residual samples from patients with hematological abnormalities being evaluated by
             Flow Cytometry for the presence or absence of an abnormal population associated with a
             hematological malignancy. All subjects of any ethnicity, age and racial background
             will be included.

        Exclusion Criteria:

          -  Specimens and/or spent samples that are visibly hemolyzed

          -  Specimens and/or spent samples that are visibly clotted

          -  Specimens and/or spent samples collected in K2EDTA anticoagulant older than 24 hours
             from time of collection

          -  Specimens and/or spent samples collected in Heparin or ACD anticoagulant older than 48
             hours from time of collection

          -  Samples with insufficient volume to complete the protocol tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Padurean, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeoGenomics Laboratories, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mike Keeney</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Luider</last_name>
    <role>Principal Investigator</role>
    <affiliation>Calgary Laboratory Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kern</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich Leukemia Laboratory</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoyan Cheng, PhD</last_name>
    <phone>305.380.2694</phone>
    <email>gcheng@beckman.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid C Smit, MS</last_name>
    <phone>305.380.2582</phone>
    <email>acmit@beckman.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NeoGenomics Laboratories, Inc.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Padurean, MD</last_name>
      <phone>239-768-0600</phone>
      <phone_ext>2342</phone_ext>
      <email>adrian.padurean@neogenomics.com</email>
    </contact>
    <investigator>
      <last_name>Adrian Padurean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calgary Laboratory Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Luider</last_name>
      <phone>403.944.8995</phone>
      <email>Joanne.luider@cls.ab.ca</email>
    </contact>
    <investigator>
      <last_name>Joanne Luider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike Keeney</last_name>
      <phone>519.685.8300</phone>
      <phone_ext>57449</phone_ext>
      <email>Mike.Keeney@LHSC.ON.CA</email>
    </contact>
    <investigator>
      <last_name>Mike Keeney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Munich Leukemia Laboratory</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Kern, MD</last_name>
      <phone>+49-89-990170</phone>
      <email>wolfgang.kern@mll.com</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Kern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematological diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

